中國高科(600730.SH)控股股東5.20%股份被司法凍結
格隆匯12月6日丨中國高科(600730.SH)公佈,2019年12月6日,公司收到上海證券交易所轉發的中國證券登記結算有限責任公司上海分公司《股權司法凍結及司法劃轉通知》及甘肅省蘭州市中級人民法院《協助執行通知書》,獲悉公司控股股東方正集團所持有的部分公司股份3048.2984萬股無限售流通股(佔公司總股本的5.20%)被司法凍結。
截至本公告披露日,方正集團持有公司股份數為1.17億股,佔公司總股本的比例為20.03%;其中,通過中信證券股份有限公司客户信用交易擔保證券賬户持有股份數為8700萬股,通過普通證券賬户持有股份數為3048.2984萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.